CIENCIASMEDICASNEWS

martes, 28 de abril de 2026

2026 Family Heart Global Summit October 2 & 3, 2026 | San Diego, CA

https://www.familyheartsummit.org/event/743c2275-3b7b-442d-adcc-c5d8b9040207/summary Announcing Keynote Speaker Valentín Fuster, MD, PhD The Family Heart Foundation cordially invites you to join us for our 12th annual Family Heart Global Summit® on October 2 & 3, 2026 in San Diego, California. We are honored to feature Dr. Valentín Fuster as a keynote speaker at the 2026 Family Heart Global Summit. Widely regarded as one of the most influential leaders in cardiovascular medicine, Dr. Fuster has played a central role in shaping how heart disease is understood, prevented, and managed worldwide. The Summit convenes leaders across research, clinical care, industry, and the patient community to advance the prevention of cardiovascular disease, with a focus on LDL cholesterol, familial hypercholesterolemia, and high lipoprotein(a). Join us for a dynamic program bringing together experts across disciplines to shape the future of cardiovascular health. Small Steps and Giant Leaps: Charting a Course for Cardiovascular Disease Prevention

Combination therapy doubles one-year survival in pancreatic cancer trial

Combination therapy doubles one-year survival in pancreatic cancer trial Findings from the randomized trial suggest that modulating the tumour microenvironment alongside chemotherapy may offer a new strategy for improving outcomes in pancreatic cancer https://www.drugdiscoverynews.com/combination-therapy-doubles-one-year-survival-in-pancreatic-cancer-trial-17121?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9RiEgzqG9BeKuO8WgnmSKpSqzPzTpSI9AbY17AuDEDKdDSUrIjlVCO8YgrLjYA3YPQMpNYgKswuehIRq3e_fQVVk1tNA&_hsmi=416164333&utm_content=416164333&utm_source=hs_email A drug developed at Northwestern University has shown a promising survival advantage in patients with metastatic pancreatic cancer, a disease that remains among the deadliest solid tumours and is projected to become the second leading cause of cancer-related deaths in the US within the next decade.

How fecal microbiota transplantation could transform cancer immunotherapy

How fecal microbiota transplantation could transform cancer immunotherapy Emerging clinical trials suggest that the gut microbiome plays a decisive role in how patients respond to immunotherapy. https://www.drugdiscoverynews.com/how-fecal-microbiota-transplantation-could-transform-cancer-immunotherapy-17017?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_hvwvtjeaeQ8I5BJ6BizhL7blcUinEmyYuCIES5SxcSnhKdq_yUK-WNzR4ESQrFVU2dgWmmh5slJMDVTPWOomx5RSqOQ&_hsmi=416164333&utm_content=416164333&utm_source=hs_email Over the past decade, scientists have learned that cancer is not driven by tumor cells alone. Disruptions in the gut microbiome have been linked to cancer development and progression through effects on genomic stability, immune evasion, and the tumor microenvironment.

Dissecting the Bladder Tumour Microenvironment with MB49 21st January 2026

Dissecting the Bladder Tumour Microenvironment with MB49 21st January 2026 Cell lines Introduction Immunotherapy has started to transform bladder cancer treatment, but durable responses remain the exception rather than the rule. Understanding why requires models that capture the tumour microenvironment, not just tumour growth. This blog explores how the MB49 syngeneic bladder cancer model – across subcutaneous, orthotopic, MB49-luc, and metastatic formats – dissects myeloid-dominated “cold” TMEs, neutrophil-driven immune escape, BCG response, and PD-L1-dependent checkpoint timing. https://cancertools.org/dissecting-bladder-tumour-microenvironment-with-mb49/?utm_term=3rd%20party%20-%20DDN%20-%20MB49%20blog&utm_campaign=43046019-Bladdercancer_DM_BrandAwareness_ALL_2026&utm_medium=3rd%20party%20-%20DDN%20-%20MB49%20blog&_hsenc=p2ANqtz--FJN0fijn2qnnW93DyMevFIKuE7zjKxplXeN_tIUh52Ae7k9kLYqHh46kHvpVUZFt95kA8wDpij8WmRUYr3TubgDVI_g&_hsmi=416164333&utm_content=3rd%20party%20-%20DDN%20-%20MB49%20blog&utm_source=3rd%20party%20-%20DDN%20-%20MB49%20blog

Gut microbes may flag Parkinson’s risk years before symptoms appear

Gut microbes may flag Parkinson’s risk years before symptoms appear Researchers have identified a distinctive gut microbiome pattern linked to Parkinson’s disease that appears in both diagnosed patients and a subset of symptom-free individuals who may already be on a disease trajectory. https://www.drugdiscoverynews.com/gut-microbes-may-flag-parkinson-s-risk-years-before-symptoms-appear-17139 Parkinson’s disease (PD) is usually diagnosed only after movement problems appear, when more than half of dopamine-producing neurons in the brain have already been lost. By that point, the biological processes driving degeneration have likely been underway for years. A new international study, published in Nature Medicine, suggests those early changes may be detectable not in the brain, but in the gut.

How an enzyme helps lung cancer survive radiation, and how to stop it

How an enzyme helps lung cancer survive radiation, and how to stop it Researchers identified a mitochondrial enzyme that shields lung cancer cells from a radiation-induced cell death process — and then found that an existing arthritis drug can disable that shield. https://www.drugdiscoverynews.com/how-an-enzyme-helps-lung-cancer-survive-radiation-and-how-to-stop-it-17144 Radiation therapy is among the most widely used treatments for lung cancer, but its effectiveness is frequently undermined by a familiar problem: Tumors that initially respond to treatment develop resistance and begin growing again. How exactly that resistance forms has remained incompletely understood, and the mechanisms that allow cancer cells to survive radiation-induced damage continue to be an active area of investigation.